Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

vandetanib 7Sorafenib 6Magnetic Resonance Spectroscopy 6lenvatinib 5cabozantinib 5Sunitinib 4Iodine-131 4selpercatinib 3AZD 6244 3trametinib 2tipifarnib 2durvalumab 2dabrafenib 2alectinib 2Triiodothyronine 2Thyroxine 2Thyrotropin Alfa 2Paclitaxel 2Nivolumab 2Ipilimumab 2Fluorodeoxyglucose F18 2Everolimus 2Bortezomib 2Axitinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tremelimumab 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thyroid Neoplasms × CUDC-907 × Clear all
NCT03002623 2018-12-21

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
7 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡